Search the Newsreel

Lynas Rare Earths Stock And 2 Australian Miners With Strong Earnings Growth

USA Rare Earth (NASDAQ:USAR) Shares Up 7.5% - What's Next?

MP Materials, USA Rare Earth Stock Rise Amid Trump Drone News; Energy Fuels Touted

Today's move appears linked to President Donald Trump's late-Thursday announcement of tariffs on drone imports and components. Drones are becoming a significant source of demand for rare earth magnets. Sentiment has been turning positive for rare earth stocks, driven by Trump administration support, corporate …

Rare Earth Stocks Soar on Friday: MP Materials Up 8%, USA Rare Earth Up 9%, NioCorp Up 3%. What's Behind the Jump?

Quick Read MP Materials surged 8% and USA Rare Earth jumped 9% Friday on trader speculation about U.S. tariff support, with no confirmed catalyst. Rare earth stocks price in tariff probability before any announcement, rewarding holders if policy lands but punishing them sharply if …

USA Rare Earth Gains 7%, MP Materials Jumps 8%: Here's Why Critical Minerals Are Moving Today

Analysts Issue Forecasts for USA Rare Earth FY2028 Earnings

Ultragenyx (RARE): RTW Investments and Roderick Wong report 7.9% stake

RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 7.9% in Ultragenyx Pharmaceutical Inc., totaling 7,796,895 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, which are held by funds advised …

Rainbow Rare Earths Directors Report Routine Share Dealing

Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside

Ultragenyx Pharmaceutical Inc.'s average 12-month price target has been slightly reduced to $52 from $52.84 by 18 analysts. This new target implies a potential upside of approximately 97% based on the August 13th closing price. The consensus analyst rating remains a "Buy" from 19 …

Ultragenyx awaits two FDA decisions that could boost its stock to $32 from $27.

Ultragenyx Pharmaceutical is awaiting two crucial FDA decisions that could significantly impact its stock price, potentially raising it from $27 to $32 per share. The decisions involve gene therapy DTX401 for glycogen storage disease type Ia, with an 80% approval chance, and UX111, with …

Heavy Rare Earths Limited Amends Entitlement Offer Timetable in Updated Securities Filing

Heavy Rare Earths Limited Revises Entitlement Offer Schedule in Latest ASX Filing

Heavy Rare Earths Updates Timetable for Entitlement Offer and Placement

Ultragenyx Stock Looks Undervalued Ahead Of Two FDA Decisions (NASDAQ:RARE)

Ultragenyx Pharmaceutical (RARE) is considered undervalued with a "soft Buy" rating and a probability-weighted fair value of approximately $32 per share, against its current price near $27. The company is anticipating two crucial FDA decisions soon: one for DTX401 on August 23rd and another …

¿Está USA Rare Earth (USAR) redefiniendo discretamente las cadenas de suministro occidentales de tierras raras con su apuesta por Serra Verde?

JL Mag Rare-Earth Co., Ltd. Unsponsored ADRs, each representing 6 ordinary shares (JMREY.US), will release their financial results after the market close on August 19.

Hunt for rare earths gets harder as JL MAG quits Australia deal

Is USA Rare Earth (USAR) Quietly Redefining Western Rare-Earth Supply Chains With Serra Verde Bet?

USA Rare Earth (NASDAQ:USAR) Trading 1.1% Higher - What's Next?

Ultragenyx (RARE): AQR Capital discloses 6.56M-share, 6.66% ownership stake

AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a passive ownership stake in Ultragenyx Pharmaceutical Inc. They beneficially own 6,560,809 shares, which constitutes 6.66% of Ultragenyx’s common stock. The filing, a SCHEDULE 13G, indicates shared voting power over 6,398,809 shares …

USA Rare Earth Q3 EPS Forecast Cut by Northland Securities

Lynas Rare Earths (ASX:LYC) Shares May Be 24% Undervalued On Cash Flow

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Lynas Rare Earths has delivered a 146.7% return over the past three years, yet investors now face mixed valuation signals as the Discounted Cash Flow …

California State Teachers Retirement System Has $1.76 Million Stock Holdings in USA Rare Earth Inc. $USAR

USA Rare Earth (NASDAQ:USAR) Trading Down 2.6% - Here's What Happened

Arafura Rare Earths (ASX:ARU) Nolans Project Progress Keeps Strategic Minerals Focus

Ultragenyx reaches settlement on DOJOLVI patent litigation with Esjay Pharma

Ultragenyx Pharmaceutical Inc. has settled patent litigation with Baylor Research Institute and Esjay Pharma regarding its drug DOJOLVI. The agreement grants Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI starting January 1, 2033, with a potential extension to July 1, …

USA Rare Earth (USAR) Stock Price Reflects Funding Risk More Than Q2 Progress

Lynas Rare Earths (ASX:LYC) Heavy Rare-Earth Push Could Put Australia at the Centre of Global Supply Chains

Heavy Rare Earths updates market on high‑grade Subron project

JL MAG Rare-Earth Delays Board Meeting to Review Interim Results

USA Rare Earth stock falls 9.4% after missing Q2 revenue and loss estimates

USA Rare Earth shares dropped 9.4% in after-hours trading after reporting Q2 2026 results that missed analyst expectations for revenue and adjusted net loss. The company posted an operating loss of $46.314 million and revenue of $5.821 million, falling short of estimates. Despite the …

USA Rare Earth Stock (USAR) Opinions on Second-Quarter Earnings Report

USA Rare Earth Stock Falls After Q2 Miss on Both Top and Bottom Lines

USA Rare Earth (NASDAQ:USAR) shares fell after the company reported a Q2 adjusted loss of 15 cents per share and revenue of $5.82 million, missing consensus estimates of 13 cents per share loss and $8.05 million revenue, respectively. Despite the financial miss, the company …